Filtered By:
Source: Circulation
Condition: Atrial Fibrillation

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 235 results found since Jan 2013.

Highlights From the Circulation Family of Journals.
Authors: Abstract This month's highlights from the subspecialty journals cover atrial fibrillation, microvascular dysfunction, progression of atherosclerosis, a stroke quality initiative, and a subanalysis of DAPAHF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure). Applying an artificial intelligence algorithm to sinus rhythm ECGs independently predicts atrial fibrillation in a study from Circulation: Arrhythmia and Electrophysiology. In Circulation: Genomic and Precision Medicine, the association of alcohol ...
Source: Circulation - January 26, 2021 Category: Cardiology Tags: Circulation Source Type: research

Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy: Results from the CABANA Trial.
Conclusions: Clinically relevant treatment-related strategy differences in the primary and secondary clinical outcomes of CABANA were not seen between men and women, and there were no sex differences in adverse events. The CABANA trial results support catheter ablation as an effective treatment strategy for both women and men. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT00911508. PMID: 33499668 [PubMed - as supplied by publisher]
Source: Circulation - January 27, 2021 Category: Cardiology Authors: Russo AM, Zeitler EP, Giczewska A, Silverstein AP, Al-Khalidi HR, Cha YM, Monahan KH, Bahnson TD, Mark DB, Packer DL, Poole JE, CABANA Investigators Tags: Circulation Source Type: research

Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results from the CABANA Trial.
Conclusions: In patients with atrial fibrillation enrolled in CABANA who had clinically diagnosed stable heart failure at trial entry, catheter ablation produced clinically important improvements in survival, freedom from AF recurrence, and quality of life relative to drug therapy. These results, obtained in a cohort most of whom had preserved left ventricular function, require independent trial verification. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique Identifier: NCT00911508. PMID: 33554614 [PubMed - as supplied by publisher]
Source: Circulation - February 8, 2021 Category: Cardiology Authors: Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, Poole JE, Bahnson TD, Lee KL, Mark DB Tags: Circulation Source Type: research

Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Circulation. 2021 Jun 21:CIR0000000000000988. doi: 10.1161/CIR.0000000000000988. Online ahead of print.ABSTRACTObstructive sleep apnea (OSA) is characterized by recurrent complete and partial upper airway obstructive events, resulting in intermittent hypoxemia, autonomic fluctuation, and sleep fragmentation. Approximately 34% and 17% of middle-aged men and women, respectively, meet the diagnostic criteria for OSA. Sleep disturbances are common and underdiagnosed among middle-aged and older adults, and the prevalence varies by race/ethnicity, sex, and obesity status. OSA prevalence is as high as 40% to 80% in patients with ...
Source: Circulation - June 21, 2021 Category: Cardiology Authors: Yerem Yeghiazarians Hani Jneid Jeremy R Tietjens Susan Redline Devin L Brown Nabil El-Sherif Reena Mehra Biykem Bozkurt Chiadi Ericson Ndumele Virend K Somers American Heart Association Council on Clinical Cardiology; Council on Peripheral Vascular Diseas Source Type: research

Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure
Conclusions: Rhythm control therapy conveys clinical benefit when initiated within one year of diagnosing atrial fibrillation in patients with signs or symptoms of heart failure. Clinical Trial Registration: Unique Identifiers: ISRCTN04708680, NCT01288352, EudraCT2010-021258-20, Study web site www.easttrial.org; URLs: www.controlled-trials.com; https://clinicaltrials.gov; https://www.clinicaltrialsregister.eu.PMID:34328366 | DOI:10.1161/CIRCULATIONAHA.121.056323
Source: Circulation - July 30, 2021 Category: Cardiology Authors: Andreas Rillig Christina Magnussen Ann-Kathrin Ozga Anna Suling Axel Brandes G ünter Breithardt A John Camm Harry J G M Crijns Lars Eckardt Arif Elvan Andreas Goette Michele Gulizia Laurent Haegeli Hein Heidbuchel Karl-Heinz Kuck Andre Ng Lukasz Szumowsk Source Type: research

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research